

# CITATION REPORT

List of articles citing

## Recent developments in Alzheimer's disease therapeutics

DOI: 10.1186/1741-7015-7-7  
BMC Medicine, 2009, 7, 7.

**Source:** <https://exaly.com/paper-pdf/45877913/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
137	Development of a high-throughput assay for screening of gamma-secretase inhibitor with endogenous human, mouse or Drosophila gamma-secretase. <i>Molecules</i> , <b>2009</b> , 14, 3589-99	4.8	9
136	Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. <b>2009</b> , 9, 1413-31		108
135	Packages of care for dementia in low- and middle-income countries. <b>2009</b> , 6, e1000176		59
134	Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. <b>2009</b> , 50, 1887-94		342
133	Current awareness in geriatric psychiatry. <b>2009</b> , 24, i-x		
132	Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. <b>2009</b> , 1, 371-80		278
131	Versatile somatic gene transfer for modeling neurodegenerative diseases. <b>2009</b> , 16, 329-42		10
130	Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." The blood-brain barrier: a physical and conceptual challenge. <b>2009</b> , 5, 435-6		4
129	Neurodegenerative disorders and nanoformulated drug development. <b>2009</b> , 4, 541-55		51
128	Neurobiology of cognitive disorders. <b>2009</b> , 22, 546-51		20
127	AD vaccines: conclusions and future directions. <b>2009</b> , 8, 160-6		10
126	Genetic and Genomic Aspects of Alzheimer's Disease. <b>2010</b> , 19, 334-341		
125	Alzheimer disease update. <b>2010</b> , 16, 15-30		4
124	[Pharmacological properties of T-817MA, a novel neurotrophic agent, for treatment of Alzheimer's disease.]. <b>2010</b> , 136, 11-4		1
123	Vaccination as a therapeutic approach to Alzheimer's disease. <b>2010</b> , 77, 17-31		37
122	A 22-week, multicenter, randomized, double-blind controlled trial of <i>Crocus sativus</i> in the treatment of mild-to-moderate Alzheimer's disease. <b>2010</b> , 207, 637-43		161
121	Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. <b>2010</b> , 214, 201-18		35

120	Chronic psychosocial stress triggers cognitive impairment in a novel at-risk model of Alzheimer's disease. <b>2010</b> , 37, 756-63	51
119	Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. <b>2010</b> , 45, 15-22	27
118	Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. <b>2010</b> , 68, 446-53	98
117	A highly sensitive peptide substrate for detecting two A $\beta$ -degrading enzymes: neprilysin and insulin-degrading enzyme. <b>2010</b> , 190, 57-62	18
116	Structure-based design and synthesis of novel P2/P3 modified, non-peptidic beta-secretase (BACE-1) inhibitors. <b>2010</b> , 20, 1924-7	23
115	Discovery of sulfonamide-pyrazole gamma-secretase inhibitors. <b>2010</b> , 20, 2148-50	15
114	Peptide mass-assisted antibody cloning strategy for accurate characterization of potential therapeutic monoclonal antibodies against neurodegenerative diseases. <b>2010</b> , 23, 203-10	3
113	Quantitative structural MRI for early detection of Alzheimer's disease. <b>2010</b> , 10, 1675-88	45
112	Bepidil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms. <b>2010</b> , 30, 8974-83	44
111	Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. <b>2010</b> , 53, 5129-43	58
110	Murine models of Alzheimer's disease and their use in developing immunotherapies. <b>2010</b> , 1802, 847-59	55
109	Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus. <b>2010</b> , 210, 240-50	38
108	Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. <b>2010</b> , 6, 239-46	308
107	Perispinal etanercept: a new therapeutic paradigm in neurology. <b>2010</b> , 10, 985-1002	48
106	Detection of amyloid plaques targeted by USPIO-A $\beta$ -42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. <b>2011</b> , 55, 1600-9	108
105	Solanezumab for Alzheimer's disease. <b>2011</b> , 11, 787-98	35
104	The role of tau in Alzheimer's disease and related disorders. <b>2011</b> , 17, 514-24	95
103	Current perspectives on pharmacotherapy of Alzheimer's disease. <b>2011</b> , 12, 335-50	56

102	Report of the task force on designing clinical trials in early (predementia) AD. <b>2011</b> , 76, 280-6		134
101	Dimebon for Alzheimer's disease. <b>2011</b> ,		
100	Rational Therapeutics for Alzheimer's Disease and Other Dementias. <b>2011</b> , 301-311		
99	A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. <b>2011</b> , 7, 10-8		54
98	Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 3474-9	3-3	24
97	Age, Alzheimer's disease, and the big picture. <b>2011</b> , 23, 1531-4		11
96	Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease. <b>2011</b> , 23, 1376-85		10
95	Fragment-Based Drug Discovery for Diseases of the Central Nervous System. <b>2011</b> , 179-192		
94	Quantitative structure-activity relationship analysis of $\beta$ -amyloid aggregation inhibitors. <b>2011</b> , 25, 135-44		6
93	Chronic psychosocial stress accelerates impairment of long-term memory and late-phase long-term potentiation in an at-risk model of Alzheimer's disease. <b>2011</b> , 21, 724-32		23
92	Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. <b>2011</b> , 259, 834-43		80
91	Challenges of longevity in developed countries: vascular prevention of dementia as an immediate clue to tackle an upcoming medical, social and economic stretch. <b>2011</b> , 8, 275-82		6
90	The bad, the good, and the ugly about oxidative stress. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2012</b> , 2012, 163913	6.7	52
89	Cholinesterase inhibitors: a patent review (2007 - 2011). <b>2012</b> , 22, 853-69		22
88	Nanobody specific for oligomeric $\beta$ -amyloid stabilizes nontoxic form. <b>2012</b> , 33, 1320-8		24
87	Experimental inhibition of peptide fibrillogenesis by synthetic peptides, carbohydrates and drugs. <b>2012</b> , 65, 271-94		
86	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine. <b>2012</b> , 20, 6669-79		52
85	Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. <i>PLoS ONE</i> , <b>2012</b> , 7, e32616	3-7	252

84	Ligand-based design, synthesis, and biological evaluation of 2-aminopyrimidines, a novel series of receptor for advanced glycation end products (RAGE) inhibitors. <b>2012</b> , 55, 9120-35	41
83	An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease. <b>2012</b> , 14, 119-30	13
82	Amyloid- $\beta$ imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?. <b>2012</b> , 39, 202-8	27
81	The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. <b>2013</b> , 5, 25	60
80	Drug Discovery by Targeting Protein-Protein Interactions. <b>2013</b> , 1-29	0
79	Vascular disease and dementias: paradigm shifts to drive research in new directions. <b>2013</b> , 9, 76-92	92
78	Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes. <b>2013</b> , 55, 17-25	57
77	Modulation of the cannabinoid receptors by hemopressin peptides. <b>2013</b> , 92, 520-4	21
76	A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the $\beta$ -secretase inhibitor avagacestat. <b>2013</b> , 75, 136-45	11
75	Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. <b>2013</b> , 33, 4923-34	81
74	Frontal network syndrome testing: clinical tests and positron emission tomography brain imaging help distinguish the 3 most common dementia subtypes. <b>2013</b> , 28, 477-84	5
73	CHAPTER 15: Molecular Chaperones as Potential Therapeutic Targets for Neurological Disorders. <b>2013</b> , 392-413	1
72	AA2-2004 Attenuates Progressive Neuronal Loss in the Brain of Tg-betaCTF99/B6 Mouse Model of Alzheimer Disease. <b>2013</b> , 22, 31-7	7
71	Carnosine's effect on amyloid fibril formation and induced cytotoxicity of lysozyme. <i>PLoS ONE</i> , <b>2013</b> , 8, e81982	3-7 32
70	Fumanjian, a Classic Chinese Herbal Formula, Can Ameliorate the Impairment of Spatial Learning and Memory through Apoptotic Signaling Pathway in the Hippocampus of Rats with A $\beta$ -40-Induced Alzheimer's Disease. <b>2014</b> , 2014, 942917	10
69	Benefits of investment into modern medicines in Central-Eastern European countries. <b>2014</b> , 14, 71-9	8
68	Bringing rigour to translational medicine. <b>2014</b> , 10, 37-43	87
67	Social workers' and nurses' illness representations about Alzheimer disease: an exploratory study. <b>2014</b> , 28, 73-8	14

66	Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures. <b>2014</b> , 739, 83-95	60
65	Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid- $\beta$ aggregation and cytotoxicity. <b>2014</b> , 6, 8475-87	114
64	Development of a dual nanocarrier system as a potential stratagem against amyloid-induced toxicity. <b>2014</b> , 11, 1131-47	4
63	Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors. <b>2014</b> , 77, 343-50	7
62	Latrepirdine for Alzheimer's disease. <b>2015</b> , CD009524	12
61	Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease. <b>2016</b> , 50, 335-52	30
60	How fisetin reduces the impact of age and disease on CNS function. <b>2015</b> , 7, 58-82	67
59	The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced Amyloid $\beta$ Binding Antibodies on Cynomolgus Monkeys and Guinea Pigs. <b>2015</b> , 2015, 786501	4
58	Comparison of active contour and fast marching methods of hippocampus segmentation. <b>2015</b> ,	1
57	Alzheimer's disease and chronic periodontitis: is there an association?. <b>2015</b> , 15, 391-404	62
56	Simple approach to the synthesis of novel tricyclic BACE1 inhibitor warhead through $\beta$ lactam opening. <b>2015</b> , 56, 4028-4030	8
55	Targeting disordered proteins with small molecules using entropy. <b>2015</b> , 40, 491-6	58
54	Chaperonotherapy for Alzheimer's Disease: Focusing on HSP60. <b>2015</b> , 51-76	4
53	Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. <b>2015</b> , 424, 64-79	11
52	Early Signs of Pathological Cognitive Aging in Mice Lacking High-Affinity Nicotinic Receptors. <b>2016</b> , 8, 91	5
51	Design of Peptide Substrate for Sensitively and Specifically Detecting Two A $\beta$ Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153360	3-7 5
50	Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease. <b>2016</b> , 92, 224-34	136
49	Grapes and the Brain. <b>2016</b> , 139-161	

48	Synthesis and biological evaluation of 8-hydroxy-2,7-naphthyridin-2-ium salts as novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). <b>2017</b> , 8, 465-470		3
47	Molecular Pathogenesis of Alzheimer's Disease: An Update. <b>2017</b> , 24, 46-54		202
46	Research advances in the treatment of Alzheimer's disease with polysaccharides from traditional Chinese medicine. <b>2017</b> , 15, 641-652		11
45	Patents Survey: Treatment of Alzheimer's Disease Through Nanotechnology-Based Drug Delivery System. <b>2017</b> , 335-359		1
44	Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence. <b>2017</b> , 61, 289-304		66
43	Molecular and Therapeutic Targets of Genistein in Alzheimer's Disease. <b>2017</b> , 54, 7028-7041		41
42	Periodontitis as a Modifiable Risk Factor for Dementia: A Nationwide Population-Based Cohort Study. <b>2017</b> , 65, 301-305		43
41	Combined QSAR, molecular docking and molecular dynamics study on new Acetylcholinesterase and Butyrylcholinesterase inhibitors. <b>2018</b> , 74, 304-326		40
40	Multi-Faceted Role of Melatonin in Neuroprotection and Amelioration of Tau Aggregates in Alzheimer's Disease. <b>2018</b> , 62, 1481-1493		23
39	The Potential Use of Plant Natural Products and Plant Extracts with Antioxidant Properties for the Prevention/Treatment of Neurodegenerative Diseases: In Vitro, In Vivo and Clinical Trials. <i>Molecules</i> , <b>2018</b> , 23,	4.8	115
38	Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?. <b>2018</b> , 15, 1032-1035		5
37	A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. <i>Statistics in Medicine</i> , <b>2018</b> , 37, 3047-3055	2.3	15
36	Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. <i>Journal of Controlled Release</i> , <b>2018</b> , 281, 139-177	11.7	228
35	Nootropic medicinal plants: Therapeutic alternatives for Alzheimer's disease. <i>Journal of Herbal Medicine</i> , <b>2019</b> , 17-18, 100291	2.3	11
34	Advancements in nanotherapeutics for Alzheimer's disease: current perspectives. <i>Journal of Pharmacy and Pharmacology</i> , <b>2019</b> , 71, 1370-1383	4.8	69
33	Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease. <i>Journal of Pharmacy and Pharmacology</i> , <b>2019</b> , 71, 1695-1705	4.8	16
32	The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	75
31	Identification of two novel peptides with antioxidant activity and their potential in inhibiting amyloid- $\beta$ aggregation in vitro. <i>Food and Function</i> , <b>2019</b> , 10, 1191-1202	6.1	5

30	Vitamin A and Retinoic Acid in Cognition and Cognitive Disease. <i>Annual Review of Nutrition</i> , <b>2020</b> , 40, 247-272	9.9	13
29	The Potential Mechanisms of the Neuroprotective Actions of Oil Palm Phenolics: Implications for Neurodegenerative Diseases. <i>Molecules</i> , <b>2020</b> , 25,	4.8	5
28	An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases. <i>Cells</i> , <b>2020</b> , 9,	7.9	9
27	Preventing and Treating Neurological Disorders with the Flavonol Fisetin. <i>Brain Plasticity</i> , <b>2021</b> , 6, 155-166	9.5	11
26	CART mitigates oxidative stress and DNA damage in memory deficits of APP/PS1 mice via upregulating Amyloid metabolism-associated enzymes. <i>Molecular Medicine Reports</i> , <b>2021</b> , 23,	2.9	3
25	The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2021</b> , 2021, 5568011	6.7	6
24	The Design of Electronic Tagging and Tracking Solutions to Improve the Safety and Person-Centered Care for People with Dementia. <i>Lecture Notes in Computer Science</i> , <b>2020</b> , 138-148	0.9	1
23	Functional neural correlates of attentional deficits in amnesic mild cognitive impairment. <i>PLoS ONE</i> , <b>2013</b> , 8, e54035	3.7	41
22	Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. <i>PLoS ONE</i> , <b>2013</b> , 8, e72301	3.7	159
21	Therapeutic Approaches to Alzheimer's Type of Dementia: A Focus on FGF21 Mediated Neuroprotection. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 2555-2568	3.3	13
20	Protein homeostasis as a therapeutic target for diseases of protein conformation. <i>Current Topics in Medicinal Chemistry</i> , <b>2012</b> , 12, 2623-40	3	69
19	Emerging Promise of Immunotherapy for Alzheimer's Disease: A New Hope for the Development of Alzheimer's Vaccine. <i>Current Topics in Medicinal Chemistry</i> , <b>2020</b> , 20, 1214-1234	3	15
18	Effects of Mulberry on The Central Nervous System: A Literature Review. <i>Current Neuropharmacology</i> , <b>2021</b> , 19, 193-219	7.6	2
17	A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (A $\beta$ ) production. <i>Bioinformatics</i> , <b>2010</b> , 5, 122-7	1.1	5
16	Protective Effects of Citicoline and Benfotiamine Each Alone and in Combination on Streptozotocin-induced Memory Impairment in Mice. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2020</b> , 18, 81-92	3.4	6
15	Immune Modulation of Inflammation in Neurodegenerative Diseases. <i>Oxidative Stress and Disease</i> , <b>2011</b> ,		
14	Developing Drugs from Sugars. <b>2012</b> , 259-296		
13	Introduction. <b>2016</b> , 1-9		



12	Glucose and Ketone Metabolism in the Aging Brain. <b>2016</b> ,		0
11	Tapping into the Potential of Cinnamon as a Therapeutic Agent in Neurological Disorders and Metabolic Syndrome. <b>2020</b> , 273-305		
10	Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases. <i>Molecular and Cellular Pharmacology</i> , <b>2010</b> , 2, 43-46		36
9	Using Plants as a Source of Potential Therapeutics for the Treatment of Alzheimer's Disease. <i>Yale Journal of Biology and Medicine</i> , <b>2020</b> , 93, 365-373	2.4	2
8	The Role of ERK1/2 Pathway in the Pathophysiology of Alzheimer's Disease: An Overview and Update on New Developments.. <i>Cellular and Molecular Neurobiology</i> , <b>2022</b> , 1	4.6	7
7	Role of Clathrin and Dynamin in Clathrin Mediated Endocytosis/Synaptic Vesicle Recycling and Implications in Neurological Diseases.. <i>Frontiers in Cellular Neuroscience</i> , <b>2021</b> , 15, 754110	6.1	0
6	Deciphering the Molecular and Genetic Basis of Alzheimer's Disease. <b>2022</b> , 13-23		
5	Computational decision-support tools for urban design to improve resilience against COVID-19 and other infectious diseases: A systematic review.. <i>Progress in Planning</i> , <b>2022</b> , 100657	3.2	1
4	Endocytosis in Amyloid biology and Alzheimer's disease. <b>2022</b> , 111-131		0
3	Brain targeting drug delivery systems for the management of brain disorders. <b>2022</b> , 289-345		0
2	Early interventions for post-traumatic stress following musculoskeletal trauma: protocol for a systematic review and meta-analysis. <b>2022</b> , 12, e065590		0
1	The Role of Caspases in Alzheimer's Disease: Pathophysiology Implications and Pharmacologic Modulation. <b>2022</b> , 1-20		1